Cargando…
NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [(67)Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice
Background: The GRPR-antagonist-based radioligands [(67/68)Ga/(111)In/(177)Lu]NeoBOMB1 have shown excellent theragnostic profiles in preclinical prostate cancer models, while [(68)Ga]NeoBOMB1 effectively visualized prostate cancer lesions in patients. We were further interested to explore the therag...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6150197/ https://www.ncbi.nlm.nih.gov/pubmed/29137110 http://dx.doi.org/10.3390/molecules22111950 |